Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Debt to Equity (2016 - 2026)

Myriad Genetics has reported Debt to Equity over the past 9 years, most recently at $0.33 for Q4 2025.

  • Quarterly Debt to Equity rose 476.84% to $0.33 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.33 through Dec 2025, up 476.84% year-over-year, with the annual reading at $0.33 for FY2025, 476.84% up from the prior year.
  • Debt to Equity was $0.33 for Q4 2025 at Myriad Genetics, up from $0.32 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.33 in Q4 2025 and troughed at $0.05 in Q4 2023.
  • The 4-year median for Debt to Equity is $0.06 (2024), against an average of $0.11.
  • Year-over-year, Debt to Equity soared 3316.86% in 2021 and then fell 5.39% in 2024.
  • A 4-year view of Debt to Equity shows it stood at $0.12 in 2021, then tumbled by 57.39% to $0.05 in 2023, then rose by 14.9% to $0.06 in 2024, then surged by 476.84% to $0.33 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Debt to Equity are $0.33 (Q4 2025), $0.32 (Q3 2025), and $0.15 (Q2 2025).